Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
JCR Impact Factor: 0.1
Year: 2017   |   Volume: 6   |   Issue: 6   |   Page: 233-238     View issue

Wilms' tumor gene 1 in leukemia: Prognostic or predictive biomarker

Saeid Shahrabi, Behrouz Yazdanpanah, Kaveh Jaseb, Mohammad Shahjahani, Elahe Khodadi

Wilms' tumor is common in children and is caused by Wilms' tumor gene 1 (WT1). The WT1 mutation has been reported in a variety of hematologic malignancies. Changing expression of miRNA molecules has also been shown to play a role in the development of Wilms' tumor. Considering the fact that WT1 can be used as a clinical biomarker in leukemia cases, it can be a basis for immunotherapy of leukemia. WT1 is a gene that can be used as a prognostic biomarker for minimal residual disease, as well as the detection of relapse for clinical remission in leukemia. Furthermore, it can be considered as a predictive biomarker for the treatment of leukemic patients after allogeneic transplantation. This study aimed to review WT1 expression in leukemia, its involvement in miRNAs expression, as well as its importance in prognosis and treatment of leukemia.

Cite this article
Shahrabi S, Yazdanpanah B, Jaseb K, Shahjahani M, Khodadi E. Wilms' tumor gene 1 in leukemia: Prognostic or predictive biomarker. Clin Cancer Investig J. 2017;6(6):233-8.
Shahrabi, S., Yazdanpanah, B., Jaseb, K., Shahjahani, M., & Khodadi, E. (2017). Wilms' tumor gene 1 in leukemia: Prognostic or predictive biomarker. Clinical Cancer Investigation Journal, 6(6), 233-238.

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice
© Clinical Cancer Investigation Journal | Published by Polaris Publication
Online since 01 December, 2011
Editorial and Ethics Policies
Creative Commons  Open Access Journal View mobile site 
ISSN: Print -2278-1668, Online - 2278-0513